Introduction
The chimeric oncogene bcr-abl is formed by the reciprocal translocation (Philadelphia translocation) that fuses part of the breakpoint cluster gene (bcr) on chromosome 22 upstream of the Abelson tyrosine kinase (abl) gene on chromosome 9
(1). Depending on the chromosomal fusion point, Bcr-Abl proteins are expressed in three different molecular sizes, 185, 210, and 230 kDa, and are believed to be responsible for acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), and chronic neutrophilic leukemia (CNL), respectively (2-4).
Bcr-Abl is a deregulated tyrosine kinase that transforms fibroblasts and immature hematopoietic cells in vitro, and the transformed cells are tumorigenic (5) (6) (7) .
The introduction of a retrovirus vector expressing p210
Bcr-Abl and p185 Bcr-Abl into growthfactor (GM-CSF/IL-3)-dependent human (MO7E) and mouse (32D) cell lines respectively converted them rapidly to growth factor-independent cell lines (8, 9) . BcrAbl expression has been implicated in the induction of resistance of CML to apoptosis induced by antileukemic drugs (10, 11) . This oncogene has been shown to block apoptosis induced by various stimuli through suppression of mitochondrial release of cytochrome c and by blocking the cytosolic pathway that leads to activation of caspase-3 (12) (13) (14) . Additionally Bcr-Abl has been shown to regulate c-jun gene expression, activation of c-jun N-terminal kinase, and the ras pathway, which may also contribute to suppression of apoptosis, transformation and tumorigenesis (15) (16) (17) (18) . It is thus apparent that t(9,22) Philadelphia translocation modulates cellular signaling. In mammalian cells various signal transduction pathways leading to survival or death are activated depending upon extracellular stimuli.
How Bcr-Abl expression affects signaling to cytokines that either stimulate or inhibit cell growth is poorly understood. It has been shown that Bcr-Abl affects cell
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the DNA-protein complex resolved in a 6.6 % native polyacrylamide gel. The specificity of binding was examined by competition with unlabeled 100-fold excess oligonucleotide and with mutant oligonucleotide. The composition and specificity of binding were also determined by supershift of the DNA-protein complex using specific and irrelevant antibodies. The antibody-treated samples of NF-κB were resolved on a 5.5% native gel. The radioactive bands from the dried gels were visualized and quantitated by PhosphorImager (Molecular Dynamics, Sunnyvale, CA) using ImageQuant software.
Western blot analysis of NF-B proteins :
Thirty to fifty micrograms of cytoplasmic protein extracts, prepared as described (23), were resolved on 10%
SDS-PAGE gel. After electrophoresis, the proteins were electrotransferred to nitrocellulose membrane, blocked with 5% nonfat milk, and probed with IκBα, IκBβ, p50, p52, p65, and ser-32-phosphorylated IκBα polyclonal antibodies (1:3000) for 1 h. The blot was washed, exposed to HRP-conjugated secondary antibodies for 1 h, and finally detected by chemiluminescence (ECL, Amersham Pharmacia Biotech. Arlington Heights, IL).
c-Jun NH 2 -terminal kinase assay: The c-Jun kinase assay was performed by a modified method as described earlier (24) . Briefly, whole-cell extracts were prepared from TNF-treated cells, and 100 µg cytoplasmic extracts were treated with anti-JNK1 antibodies. The immune complexes were precipitated with protein A/G-Sepharose beads (Pierce, USA). The kinase assay was performed using washed beads as source of enzyme and glutathione S-transferase-Jun ( Receptor-binding assay: Human recombinant TNF was labeled with Na 125 I using the IODOGEN procedure as described (25) . The specific activity of the labeled TNF was 38 µCi/µg. The binding assays were performed by using the 96-well method as previously described (26) . Briefly, cells (0.5 x 10 6 /ml) were and then detected by chemiluminescence (ECL, Amersham).
RNase protection assay:
The expression of p60 and p80TNF receptor mRNA was determined by RNase protection assay using human cytokine receptor multi-probe template sets (hCR-4) as per manufacturer's instruction. Briefly, each cell type (5 x 10 6 ) was washed 2 times with PBS to remove medium protein.
Total RNA was isolated using TRIzol Reagent (Life Technologies, Rockville, MD).
Ten-microgram RNA samples were hybridized with 32 To ensure that the activated NF-κB in MO7E cells was composed of transcriptionally active heterodimers of p50 and p65 subunits, the TNF-treated nuclear extracts were incubated with anti-p65 or anti-p50 antibodies before EMSA. EMSA result showed that the NF-κB/DNA complex was either abrogated or supershifted when nuclear extract was treated with p50/p65
antibodies (Fig. 1C) . The DNA binding was not prevented by treatment of nuclear extracts with irrelevant cyclin D1 antibodies or pre-immune sera, indicating specificity of the heterodimer. The specificity of the TNF-induced NF-κB/DNA complex was further confirmed by demonstrating that the binding was disrupted in the presence of a 100-fold excess of unlabeled κB-oligonucleotide, but not by mutant oligonucleotide (Fig. 1C) .
Bcr-Abl does not affect the expression of various NF-B proteins:
It is possible that Bcr-Abl downregulated the expression of NF-κB proteins, making MBA cells unable to respond to TNF-induced NF-κB activation. To determine this, we prepared cytoplasmic extracts from both cell types and examined the expression of p65 (c-rel), p50, p100, IκBα, and IκBβ by western blot analysis using specific antibodies. Fig. 2A shows that all the NF-κB proteins are expressed to a similar level in both cell types, thus suggesting that Bcr-Abl had no effect on the expression of various NF-κB proteins. Rather than stimulating NF-κB by itself, Bcr-Abl suppressed TNF-induced NF-κB activation in our study. This suppression occurred through the inhibition of IκBα phosphorylation needed for NF-κB activation. This is the first report to our knowledge to indicate that Bcr-Abl can modulate the signaling of any cytokine, other than IL-3. IL-3 is known to be produced by Bcr-Abl-expressing leukemic cells and acts as an autocrine growth factor (19) . Furthermore, Bcr-Abl can interact with the IL-3 receptor beta chain and induce constitutive tyrosine phosphorylation (20) . 
Bcr-Abl does not affect the NF-B activation induced by okadaic acid:

